Imatinib Aspire (Imatinib)

Imatinib inhibits the ATP‑binding site of the BCR‑ABL tyrosine kinase as well as c‑KIT and PDGFR receptors. By blocking these enzymes, it prevents downstream signaling that promotes uncontrolled cell division, leading to reduced proliferation of leukemic and tumor cells and ultimately inducing apoptosis.

The exact dose of Imatinib Aspire is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Only a qualified prescriber should set the dosing regimen.

Safety data for Imatinib during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Imatinib Aspire product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer TKIs such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib is often preferred for its long‑term safety data and cost‑effectiveness in many health‑care settings.

Imatinib Aspire should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

Imatinib Aspire is taken orally, usually once daily, with a glass of water. It can be swallowed with or without food, although taking it with a meal may reduce gastrointestinal discomfort for some patients.

Patients should be alert for severe neutropenia or leukopenia, signs of liver injury (jaundice, dark urine), cardiac dysfunction (shortness of breath, swelling), pulmonary hypertension, and rare but serious skin reactions such as Stevens‑Johnson syndrome. Prompt medical evaluation is essential if any of these occur.

Imatinib Aspire is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled heart failure, or those receiving strong CYP3A4 inducers that could markedly lower drug exposure.